XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma

Approximately 96% of patients with glioblastomas (GBM) have IDH1 wildtype GBMs, characterized by extremely poor prognosis, partly due to resistance to standard temozolomide treatment. O6-Methylguanine-DNA methyltransferase (MGMT) promoter methylation status is a crucial prognostic biomarker for alky...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Nguyen Quoc Khanh, Do, Duyen Thi, Chiu, Fang-Ying, Yapp, Edward Kien Yee, Yeh, Hui-Yuan, Chen, Cheng-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563334/
https://www.ncbi.nlm.nih.gov/pubmed/32942564
http://dx.doi.org/10.3390/jpm10030128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563334/
https://www.ncbi.nlm.nih.gov/pubmed/32942564
http://dx.doi.org/10.3390/jpm10030128

Ejemplares similares